Staphylokinase during stroke blood-flow treatment
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial studies using a medication called non-immunogenic staphylokinase as part of standard clot-busting treatment for an acute ischemic stroke. It may help clinicians improve blood flow after the stroke using an approach designed to be less likely to trigger immune reactions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 85 years old.
- Have an acute ischemic stroke and be eligible for clot-busting (thrombolytic) treatment.
- You are planning to receive non-immunogenic staphylokinase as the clot-busting medicine, or you already received it.
- You have no known severe allergy or intolerance to staphylokinase or similar recombinant protein medicines.
- You must not have any reason you cannot receive clot-busting treatment (thrombolytic therapy contraindication).
- You are not pregnant and not breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an investigational study drug can improve outcomes after an acute ischemic stroke (a stroke caused by blocked blood flow). You may be eligible if you are able to start treatment quickly after symptom onset and have a moderate stroke severity on a standard stroke exam.
This trial tests a single dose of a new clot-dissolving medicine for people who had a stroke 4.5 to 24 hours ago. It may help if you cannot have standard treatments like a clot-removal procedure or other clot-busting drugs.
This study tests whether adding a drug called human urinary kallidinogenase to standard clot-removal therapy helps people recover better after a large-vessel stroke. If you qualify, you would receive the drug or a placebo by IV along with the procedure, and doctors will monitor your recovery.
This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.
This trial tests a new drug, staphylokinase, to see if it can break up blood clots in the lungs in people with a moderate-high risk pulmonary embolism. The goal is to improve blood flow and reduce the chance of complications.
This trial looks at giving a clot-busting medicine directly into the brain arteries (intra-arterial TNK) when a stroke procedure (thrombectomy) doesn’t reopen the blocked vessel enough. It aims to improve recovery by improving blood flow while checking for safety, especially bleeding risk.
Hear when a new Acute Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.